Price
$4.42
Decreased by -0.45%
Dollar Volume
71.96 K
ADR%
14.24
Earnings Report Date (estimate)
Sep 30, 22 (N/A)
Market Cap.
15.79 M
Shares Float
8.94 M
Shares Outstanding
13.27 M
Beta
-0.05
Price / Earnings
-6.18
BPR
10.38
20D Range
4.10 6.50
50D Range
4.00 6.87
200D Range
4.00 17.30
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 20 327.27 K
Increased by +1.13 K%
-6.20 M
Decreased by -13.05%
Decreased by -1.90 K%
Increased by +90.79%
Dec 31, 19 295.37 K - -9.60 M -
Decreased by -3.25 K%
-
Jun 30, 19 239.79 K - -9.09 M -
Decreased by -3.79 K%
-
Dec 31, 18 383.45 K - -14.83 M -
Decreased by -3.87 K%
-
Jun 30, 18 26.66 K - -5.49 M -
Decreased by -20.59 K%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.